Hepion Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Apr 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 8, 2025
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash | $406,408 | $14,785,880 |
| Prepaid expenses | 1,207,329 | 2,701,960 |
| Total current assets | 1,613,737 | 17,487,840 |
| Property and equipment, net | — | 29,487 |
| Right-of-use assets | — | 212,878 |
| Other assets | — | 364,192 |
| Total assets | $1,613,737 | $18,094,397 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $220,202 | $2,348,829 |
| Accrued expenses | 23,684 | 2,439,351 |
| Operating lease liabilities, current | — | 115,916 |
| Notes payable, current | 2,900,000 | — |
| Short-term portion of contingent consideration | — | 386,000 |
| Total current liabilities | 3,143,886 | 5,290,096 |
| Contingent consideration, non-current | — | 1,634,000 |
| Operating lease liabilities, non-current | — | 93,104 |
| Derivative financial instruments—warrants | 333,189 | 3,796,390 |
| Total liabilities | 3,477,075 | 10,813,590 |
| Commitments and contingencies (see Note 12) | - | - |
| Stockholders’ equity: | ||
| Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at December 31, 2024 and 2023, respectively. | 855,808 | 855,808 |
| Series C convertible preferred stock, stated value $1,000 per share, 1,688 shares issued and outstanding at December 31, 2024 and 2023. | 839,320 | 839,320 |
| Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 139,168 and 96,375 shares issued and outstanding at December 31, 2024 and 2023, respectively. | 14 | 10 |
| Additional paid-in capital | 234,252,981 | 230,291,834 |
| Accumulated other comprehensive income (loss) | 8,345 | (78,779) |
| Accumulated deficit | (237,819,806) | (224,627,386) |
| Total stockholders’ equity | (1,863,338) | 7,280,807 |
| Total liabilities and stockholders’ equity | $1,613,737 | $18,094,397 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.